PH177

Bader-Meunier B, Bulai Livideanu C, Larroche C, Durieu I, Artru L, Beucher A, Cormier G, Cornec D, Delarco M, Dubost JJ, Fontaine C,Gourin MP, Javier RM, de Jauréguiberry JP, Maisonneuve H, Toussirot E, Ugo V, Echaubard S, Mahlaoui N, Aouba A, Bodemer C, Briot K, Frenzel L, Lortholary O, Chandesris MO, Hermine O; CEREMAST, CRI and SOFREMIP

Association of mastocytosis with inflammatory joint diseases: a series of 31 patients.

Semin Arthritis Rheum. 2014 Dec; 44(3):362-5.

PH176

Trarieux-Signol S, Moreau S,Gourin MP, Penot A, Edoux de Lafont G, Preux PM, Bordessoule D.

Factors associated with the designation of a health care proxy and writing advance directives for patients suffering from haematological malignancies.

BMC Palliat Care. 2014 Dec 11; 13:57.

PH175

Blaise, D., Nguyen, S., Bay, J.-O., Chevallier, P., Contentin, N., Dhédin, N., Duléry, R., Eliaou, J.-F., Rubio, M.-T., Suarez, F., Bulabois, C.-E., Cornillon, J., Huynh, A., Magro, L., Michallet, M., Paillard, C., Turlure, P. and Yakoub-Agha, I.

Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (Part 1)

Pathol. Biol., 62(4), 180–184, 2014.

PH174

Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, Pautas C, Perrot A, Lioure B, Rousselot P, Tamburini J, Cluzeau T, Konopacki J, Randriamalala E, Berthon C,Gourin MP, Recher C, Cahn JY, Ifrah N, Dombret H, Boissel N.

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.

Blood. 2014 Aug 21;124(8):1312-9.

PH173

Thépot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing Koka A, Stamatoullas A,Gourin MP, Dartigeas C, Cheze S, Banos A, Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, Thomas X, Isnard F, Beve B, Chait Y, Guerci A, Vey N, Dreyfus F, Ades L, Ifrah N, Dombret H, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS).

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.

Am J Hematol. 2014 Apr;89(4):410-6.

PH172

Hu, M. I., Glezerman, I. G., Leboulleux, S., Insogna, K., Gucalp, R., Misiorowski, W., Yu, B., Zorsky, P., Tosi, D., Bessudo, A., Jaccard, A., Tonini, G., Ying, W., Braun, A. and Jain, R. K.

Denosumab for treatment of hypercalcemia of malignancy.

J. Clin. Endocrinol. Metab., 99(9), 3144–3152, 2014.

PH171

Jaccard, A. and Bridoux, F.

Amyloidosis

Rev Prat, 64(4), 575–581, 2014.

PH170

Jaccard, A., Comenzo, R. L., Hari, P., Hawkins, P. N., Roussel, M., Morel, P., Macro, M., Pellegrin, J.-L., Lazaro, E., Mohty, D., Mercie, P., Decaux, O., Gillmore, J., Lavergne, D., Bridoux, F., Wechalekar, A. D. and Venner, C. P.
Efficacy of bortezomib, cyclophosphamide and dexamethasone in III)
Haematologica, 99(9), 1479–1485, 2014.

treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage

PH169

Malak, S., Sotto, J.-J., Ceccaldi, J., Colombat, P., Casassus, P., Jaulmes, D., Rochant, H., Cheminant, M., Beaussant, Y., Zittoun, R. and Bordessoule, D.

Ethical and clinical aspects of intensive care unit admission in patients with hematological malignancies: guidelines of the ethics commission of the French society of hematology.

Adv Hematol, 2014, 704318, 2014

PH168

De Masson, A., Beylot-Barry, M., Bouaziz, J.-D., Peffault de Latour, R., Aubin, F., Garciaz, S., d’ Incan, M., Dereure, O., Dalle, S., Dompmartin, A., Suarez, F., Battistella, M., Vignon-Pennamen, M.-D., Rivet, J., Adamski, H., Brice, P., François, S., Lissandre, S., Turlure, P., Wierzbicka-Hainaut, E., Brissot, E., Dulery, R., Servais, S., Ravinet, A., Tabrizi, R., Ingen-Housz-Oro, S., Joly, P., Socié, G., Bagot, M. and French Study Group on Cutaneous Lymphomas and Société Française de Greffe de Moëlle et Thérapie Cellulaire

Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas.

Haematologica, 99(3), 527–534, 2014.

PH167

Nguyen, S., Blaise, D., Bay, J.-O., Chevallier, P., Contentin, N., Dhédin, N., Duléry, R., Eliaou, J.-F., Rubio, M.-T., Suarez, F., Bulabois, C.-E., Cornillon, J., Huynh, A., Magro, L., Michallet, M., Paillard, C., Turlure, P. and Yakoub-Agha, I.

Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (part 2)]

Pathol. Biol., 62(4), 185–189, 2014.

PH166

Rahmé, R., Thomas, X., Recher, C., Vey, N., Delaunay, J., Deconinck, E., Hirsch, P., Bordessoule, D., Micol, J.-B., Stamatoullas, A., Mariette, C., Pautas, C., Bories, P., Marolleau, J.-P., Hunault-Berger, M., Fegueux, N., Raffoux, E., Dombret, H., Degos, L., Fenaux, P. and Adès, L.

Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients.

Leukemia, 28(12), 2422–2424, 2014.

PH165

Aguilar, C., Malphettes, M., Donadieu, J., Chandesris, O., Coignard-Biehler, H., Catherinot, E., Pellier, I., Stephan, J.-L., Le Moing, V., Barlogis, V., Suarez, F., Gérart, S., Lanternier, F., Jaccard, A., Consigny, P.-H., Moulin, F., Launay, O., Lecuit, M., Hermine, O., Oksenhendler, E., Picard, C., Blanche, S., Fischer, A., Mahlaoui, N. and Lortholary, O.

Prevention of infections during primary immunodeficiency.

Clin. Infect. Dis., 59(10), 1462–1470, 2014.

PH164

Andrei, I. A., Kuntzer, T., Lobrinus, J. A., Jaccard, A. and Zufferey, P.

Neuroarthropathy of the foot revealing primary systemic amyloidosis: case report and literature review.

Clin. Rheumatol., 2014.

PH163

Belaiche, S., Yafour, N., Balcaen, S., Beguin, Y., Borel, C., Bruno, B., Godin, S., Labussiere-Wallet, H., Sanhamut, N., Charbonnier, A., de Berranger, E., Konopacki-Potet, J., Turlure, P. and Yakoub-Agha, I.

Utilisation of immunosuppressants in the prevention of a graft versus host reaction: report by the SFGM-TC.

Pathol. Biol., 62(4), 197–203, 2014.

PH162

Chanut, A., Duguet, F., Marfak, A., David, A., Petit, B., Parrens, M., Durand-Panteix, S., Boulin-Deveza, M., Gachard, N., Youlyouz-Marfak, I., Bordessoule, D., Feuillard, J. and Faumont, N.

RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells.

Leukemia, 28(4), 871–879, 2014.

PH161

Dietrich, S., Boumendil, A., Finel, H., Avivi, I., Volin, L., Cornelissen, J., Jarosinska, R. J., Schmid, C., Finke, J., Stevens, W. B. C., Schouten, H. C., Kaufmann, M., Sebban, C., Trneny, M., Kobbe, G., Fornecker, L. M., Schetelig, J., Kanfer, E., Heinicke, T., Pfreundschuh, M., Diez-Martin, J. L., Bordessoule, D., Robinson, S. and Dreger, P.

Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).

Ann. Oncol., 25(5), 1053–1058, 2014.

PH160

Döhner, H., Lübbert, M., Fiedler, W., Fouillard, L., Haaland, A., Brandwein, J. M., Lepretre, S., Reman, O., Turlure, P., Ottmann, O. G., Müller-Tidow, C., Krämer, A., Raffoux, E., Döhner, K., Schlenk, R. F., Voss, F., Taube, T., Fritsch, H. and Maertens, J.

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.

Blood, 124(9), 1426–1433, 2014.

PH159

Pauliat H., Bordessoule D., Trarieux-Signol S., Moreau S.

Affaire Vincent Lambert : au-delà de la légalité, la volonté du patient

La Semaine Juridique Administrations et Collectivités territoriales n° 41, 13 Octobre 2014, 2284

PH158

Fruchart, C., Tilly, H., Morschhauser, F., Ghesquières, H., Bouteloup, M., Fermé, C., Van Den Neste, E., Bordessoule, D., Bouabdallah, R., Delmer, A., Casasnovas, R. O., Ysebaert, L., Ciappuccini, R., Briere, J. and Gisselbrecht, C.

Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma, Biol.

Blood Marrow Transplant., 20(12), 1905–1911, 2014.

PH157

Guillaume, T., Porcheron, S., Audat, F., Bancillon, N., Berceanu, A., Charbonnier, A., Dulery, R., Edy, N., El Cheikh, J., Hermet, E., Maurer, N., Paul, F., Konopacki-Potet, J., Turlure, P., Wallart, A., Boulanger, F., Dhédin, N., Suarez, F. and Yakoub-Agha, I.

Prophylactic, preemptive and curative use of donor lymphocyte infusion in patients undergoing allogeneic stem cell transplantation: guidelines of the SFGM-TC.

Pathol. Biol., 62(4), 193–196, 2014.

PH156

Hie, M., Gay, J., Galicier, L., Provôt, F., Presne, C., Poullin, P., Bonmarchand, G., Wynckel, A., Benhamou, Y., Vanhille, P., Servais, A., Bordessoule, D., Coindre, J.-P., Hamidou, M., Vernant, J.-P., Veyradier, A., Coppo, P. and French Thrombotic Microangiopathies Reference Centre.

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.

Blood, 124(2), 204–210, 2014.

PH155

Morgand, M., Buffet, M., Busson, M., Loiseau, P., Malot, S., Amokrane, K., Fortier, C., London, J., Bonmarchand, G., Wynckel, A., Provôt, F., Poullin, P., Vanhille, P., Presne, C., Bordessoule, D., Girault, S., Delmas, Y., Hamidou, M., Mousson, C., Vigneau, C., Lautrette, A., Pourrat, J., Galicier, L., Azoulay, E., Pène, F., Mira, J.-P., Rondeau, E., Ojeda-Uribe, M., Charron, D., Maury, E., Guidet, B., Veyradier, A., Tamouza, R., Coppo, P. and Thrombotic Microangiopathies Reference Center.

High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center.

Transfusion, 54(2), 389–397, 2014.

PH154

Woillard, J.-B., Lebreton, V., Neely, M., Turlure, P., Girault, S., Debord, J., Marquet, P. and Saint-Marcoux, F.

Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients.

Br J Clin Pharmacol, 78(4), 836–846, 2014.

PH153

Rizzo, D., Lotay, A., Gachard, N., Marfak, I., Faucher, J.-L., Trimoreau, F., Guérin, E., Bordessoule, D., Jaccard, A. and Feuillard, J.

Very low levels of surface CD45 reflect CLL cell fragility, are inversely correlated with trisomy 12 and are associated with increased treatment-free survival.

Am. J. Hematol., 88(9), 747–753, 2013

PH152

Rubio, M.-T., Charbonnier, A., de Berranger, E., Gandemer, V., Magro, L., Maury, S., Sterkers, G., Suarez, F., Dalle, J.-H., Daguindau, E., Galumbrun, C., Hermet, É., Reman, O., Turlure, P., Yakoub-Agha, I. and French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC).

Vaccination post hematopoietic stem cell transplantation: which vaccines and when and, how to vaccinate? An SFGM-TC report.

Pathol. Biol., 61(4), 139–143, 2013

PHR43

Gallot, G., Vollant, S., Saïagh, S., Clémenceau, B., Vivien, R., Cerato, E., Bignon, J.-D., Ferrand, C., Jaccard, A., Vigouroux, S., Choquet, S., Dalle, J.-H., Frachon, I., Bruno, B., Mothy, M., Mechinaud, F., Leblond, V., Milpied, N. and Vié, H.

T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study.

J. Immunother., 37(3), 170–179, 2014

PHR42

Beldjord, K., Chevret, S., Asnafi, V., Huguet, F., Boulland, M.-L., Leguay, T., Thomas, X., Cayuela, J.-M., Grardel, N., Chalandon, Y., Boissel, N., Schaefer, B., Delabesse, E., Cavé, H., Chevallier, P., Buzyn, A., Fest, T., Reman, O., Vernant, J.-P., Lhéritier, V., Béné, M. C., Lafage, M., Macintyre, E., Ifrah, N., Dombret, H. and Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

Blood, 123(24), 3739–3749, 2014.

PHR41

Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J.-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., Facon, T. and FIRST Trial Team.
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
N. Engl. J. Med., 371(10), 906–917, 2014.

PHR40

Bertoli, S., Bories, P., Béné, M. C., Daliphard, S., Lioure, B., Pigneux, A., Vey, N., Delaunay, J., Leymarie, V., Luquet, I., Blanchet, O., Cornillet-Lefebvre, P., Hunault, M., Bouscary, D., Fegueux, N., Guardiola, P., Dreyfus, F., Harousseau, J. L., Cahn, J. Y., Ifrah, N., Récher, C. and Groupe Ouest-Est d’Etude des Leucémies Aiguës et Autres Maladies du Sang (GOELAMS)

Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group.

Haematologica, 99(1), 46–53, 2014

PHR39

Rey, J., Viallard, J.-F., Keddad, K., Smith, J., Wilde, P., Kiladjian, J.-J. and FOX study investigators.

Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.

Eur. J. Haematol., 92(2), 127–136, 2014

PHR38

Mounier, N., Brice, P., Bologna, S., Briere, J., Gaillard, I., Heczko, M., Gabarre, J., Casasnovas, O., Jaubert, J., Colin, P., Delmer, A., Devidas, A., Bachy, E., Nicolas-Virelizier, E., Aoudjhane, A., Humbrecht, C., Andre, M., Carde, P. and Lymphoma Study Association (LYSA)
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.

Ann. Oncol., 25(8), 1622–1628, 2014.

PHR37

Gathmann, B., Mahlaoui, N., CEREDIH, Gérard, L., Oksenhendler, E., Warnatz, K., Schulze, I., Kindle, G., Kuijpers, T. W., Dutch WID, van Beem, R. T., Guzman, D., Workman, S., Soler-Palacín, P., De Gracia, J., Witte, T., Schmidt, R. E., Litzman, J., Hlavackova, E., Thon, V., Borte, M., Borte, S., Kumararatne, D., Feighery, C., Longhurst, H., Helbert, M., Szaflarska, A., Sediva, A., Belohradsky, B. H., Jones, A., Baumann, U., Meyts, I., Kutukculer, N., Wågström, P., Galal, N. M., Roesler, J., Farmaki, E., Zinovieva, N., Ciznar, P., Papadopoulou-Alataki, E., Bienemann, K., Velbri, S., Panahloo, Z., Grimbacher, B. and European Society for Immunodeficiencies Registry Working Party

Clinical picture and treatment of 2212 patients with common variable immunodeficiency

J. Allergy Clin. Immunol., 134(1), 116–126, 2014.

PHR36

Awan, F. T., Hillmen, P., Hellmann, A., Robak, T., Hughes, S. G., Trone, D., Shannon, M., Flinn, I. W., Byrd, J. C. and LUCID trial investigators.

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Br. J. Haematol., 167(4), 466–477, 2014.

PHR35

Dombret H., Seymour JF., Butrym A., Wierzbowska A., Selleslag D.,Ho Jang J.,Kumar R., Cavenagh J., Schuh A., Candoni A., Récher C., Sandhu I., Bernal T., Al-Ali H., Martinelli G, Stone R., Minden MD., McIntyre H., Songer S., Lucy L., Beach CL, Döhner H.

Results of a phase 3, multicenter, randomized, open-label study of azacitidine (aza) vs conventional care regimens (CCR) in older patients with newly Diagnosed acute myeloid leukemia (AML).

19th Congrès of EHA European Hematology Association, Milan Italie, 12-15 June 2014

PHR34

Etienne G., Huguet F., Guerc-Bresler A., Nicolini F., Maloisel F., Coiteux V., Dauriac C., Carpenter N., Bourdeix I., Tulliez M., Cany-Makhoul P.

Epidemiological cross sectionneal survey of first line treated patients with chronic myeloid leukemia in chronic phase (CML P) I routine consultations during a one month period : EPIDOR french survey.

Haematologica j 2014:99 (S1) p 606-607

CH290

Kastritis E., Leleu X., Arnulf B., Zamagni E., Mollee P., Cibeira MT, O Schönland S., Moreau P., Hajek R., Jaccard A., Nicolas-Virelizier E., Filshie R., Augustson B, Mateos MV., Milani P., Meletios A. Dimopoulo M., Hachulla E., Fermand JP., Foli A., Palumbo A., Sonneveld P., Johnsen HE., Merlini G., and Palladini G.

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis.

56^ème Congrès de l’American Society of Hematology, San Francisco 6-9 Décembre 2014

CH289

Jaccard A., Lazareth A., Karlin L., Choquet S., Frenzel L., Garderet L., Dib M., Galicier L., Tournilhac O., Belhadj K., Moreau P., Decaux O., Benboubker L., Cogné M., Musset L., Fermand JP.

A Prospective Phase II Trial of Lenalidomide and Dexamethasone (LEN-DEX) in POEMS Syndrome.

56^ème Congrès de l’American Society of Hematology, San Francisco 6-9 Décembre 2014

CH288

Meletios A. Dimopoulos MA, M., Roussel M., Liu T., Gamberi B., Kolb B., Derigs HG., Seok Eom H. Belhadj K., Lenain P., H. van der Jagt R., Rigaudeau S., Dib M., Hall R., Jaccard A., Tosikyan A.,Karlin L., Bensinger W., Rik Schots R., Chen G., Marek J., Ervin-Haynes A.,Thierry Facon T.

Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results.

56^ème Congrès de l’American Society of Hematology, San Francisco 6-9 Décembre 2014

CH287

Jaccard A., Bridoux F., Lazaro E., Tournilhac O., Macro M., Roussel M., Moulin B., Leleu X., Did M., Choquet S., Morel P., Royer B., Lavergne D., Rigaud C., Fermand JP.

Risk and Response Adapted Conventional Treatment Strategy in 146 Patients with AL Amyloidosis.

56^ème Congrès de l’American Society of Hematology, San Francisco 6-9 Décembre 2014

CH286

Merlini G., Sanchorawala V., Jeffrey ZA., Kukreti V., O Schoenland S., Jaccard A., Dispenzieri A., D. Cohen A., Berg D., Yuan Z., Hui AM., Giovanni P, Comenzo RL.

Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL).

56^ème Congrès de l’American Society of Hematology, San Francisco 6-9 Décembre 2014

CH285

Lazarovici J., Brice P., Obéric L., Gaillard I., Hunault-Berger M., Broussais F., Bologna S., Gyan E., Sebban C. Touati M., , Delarue R., Orsini-Piocelle F., Stamatoullas A. , Dartigues P., PE André M., Casasnovas O., Mounier N., Fermé C.

Management and Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Retrospective Study By the Lymphoma Study Association

56^ème Congrès de l’American Society of Hematology, San Francisco 6-9 Décembre 2014

CH284

Czerw T., Labopin M., Schmid C., Cornelissen J., Chevallier P., Blaise D., Kuball J., Milpied N., Cahn J Y., Lioure B., Fegueux N., Clement L., Sandstedt A., Maertens J., Guillerm G., Bordessoule D., Mohty M., Nagler A.

Impact of CD3+ and CD34+ Doses in the Mobilized Peripheral Blood Stem Cell Grafts on the Outcome of Reduced-Intensity Conditioning Allogenic Transplantation from Matched Unrelated Donors for Acute Myeloid Leukemia – an Analysis from the Acute Leukemia Working Party of the EBMT.

56^ème Congrès de l’American Society of Hematology, San Francisco 6-9 Décembre 2014

CH283

Avivi I., Boumendil A., Finel H., Nagler A., Sousa Bothello A., Ribera Santasusana J M., Vandenberghe E., Afanasyev B., Bordessoule D., Moraleda J M., Conde E., Pohlreich D., Dreger P.

Autologous Stem Cell Transplantation for Primary Mediastinal B Cell Lymphoma in the Rituximab Era: A Retrospective Study By the EBMT Lymphoma Working Party

56^ème Congrès de l’American Society of Hematology, San Francisco 6-9 Décembre 2014

CH282

Touati M., Assenat J., Monteil J., De Souza P., Munyamahoro M., Juge S., Preux PM., Jaccard A.,

CHBordessoule D.

An Interactive 3D Lymphoma's Stage Calculator Assistant: A New Tool to Help Hematologists in Routine Practice.

56^ème Congrès de l’American Society of Hematology, San Francisco 6-9 Décembre 2014

CH281

Karlin L., Bienvenu J., Casasnovas RO., Delfau-Larue MH., Feugier P. , Dupuis J., Rabeony T., Ferme C., Sebban C., Soubeyran P., Cartron G., Delmer A., Bordessoule D., Brice P., Lamy T., Bousseta S., Tilly H., Salles GA.

Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study

56^ème Congrès de l’American Society of Hematology, San Francisco 6-9 Décembre 2014

CH280

Signol N., Pham Dang A., Fargeas JB., Picat MA., Penot A., Vallejo C., Dantoine T., Bordessoule D.

Disruption of the clinical care pathway in geriatric hematology: impact of the Comprehensive Geriatric Assessment.

International Society of Geriatric Oncology (SIOG), Lisbonne, 23-25 Octobre 2014

CH279

Fargeas JB. Abraham J., Olivrie A., Picat MA., Touati M., Signol N., Jaccard A, Bordessoule D.

Crash score in the older french non hodgkin lymphoma receiving chemotherapy, first results. International Society of Geriatric Oncology (SIOG), Lisbonne, 23-25 Octobre 2014

CH278

Plat A., Bathias M., Trimoreau F., Girault S., Turlure P., Feuillard J., Donnard M.

Utilisation des ADVIA 2120i pour les numérations de cellules nucléées totales en thérapie cellulaire : quelles performances ?

SFGM TC

CH277

Bentayeb H., Dubanet L., Thuaud F., Désaubry L., de Gramont A., Raymond E., Petit B., Olivrie A., Bordessoule D.,Jauberteau MO, Troutaud D.

Evaluation du potentiel antitumoral d’une flavine de synthèse (FL3) dans les modèles cellulaires et animaux de lymphomes diffus à grandes cellules (DLBCL).

10^ème journées du Cancéropole GSO, Toulouse ,16-17 Octobre 2014

CH276

Touati M., Boulesteix M., Abraham J., Olivrie A., Verbeke S., Delage-Corre M., Bordessoule D., Monteil J.
Initial FDG Metabolic Tumor Volume: a new EFS predictor factor in Hodgkin Lymphoma.
5th International Workshop on PET in Lymphoma, Menton, September 19-20th 2014

CH275

S Trarieux-Signol, S Moreau,
Quels sens pour les soins palliatifs en 2014? Regards croisés sur la place de la médecine, de la société et de la personne à l’horizon d’une nouvelle législation sur la fin de vie.

20ème Journée de formation continue en soins palliatifs du limousin, Faculté de médecine, Limoges, France juin 2014

Communication orale

CH274

Zygar M, Aupetit S, Daly N, Philippon C, Penot A, Gourin MP, Moreau S, Bordessoule D

Médecine alternative (sophrologie, socio-esthétique, réflexologie) et bien-être des patients atteints d’hémopathies malignes.

20^ème Congrès de la Société Française d’Accompagnement et de Soins Pallialtifs, Montpellier, 18-20 juin 2014

Poster affiché

CH273

Zygar M,

Médecine alternative et bien-être des patients atteints d’hémopathies malinges.

20^ème Congrès de la Société Française d’Accompagnement et de Soins Pallialtifs, Montpellier, 18-20 juin 2014

Communication orale

CH272

Penot A,

Pratique des soins de support et soins palliatifs en hôpital de jour d’hématologie

20^ème Congrès de la Société Française d’Accompagnement et de Soins Pallialtifs, Montpellier, 18-20 juin 2014

Communication orale

CH271

Trarieux-Signol S

Regards croisés patients-soignants sur les directives anticipées

10^ème conférence internationale d’éthique clinique, Paris, avril 2014

Communication orale

CH270

S Trarieux-Signol, MP Gourin, M Touati, D Bordessoule.

Les apports d’un Comité de patients régional en hématologie,

10^ème conférence internationale d’éthique clinique, Paris, avril 2014

CH269

Tardieu L., Bompoint C., Contentin N., Cornillon J., Deconinck E., Dendoncker C., Godin S., Guiraud M., Huyhn A., Magro L., Maillard N., Milpied N., Porcheron S., Recchia E., Rubio MT, Samy JP, Tipton R., Olivrie A., Wallart A., Yakoub-Agha A and SFGM-TC.

National post-transplant follow-up care logbook for patients undergoing allogenic hematopoietic stem cell transplantation: an initiative by the SFGM-TC.

40^ème Congrès European Bone Marrow transplantation, Milan, Italy 30 Mars– 2 Avril 2014

CH268

Tardieu L., K Vauzelle K., Otmane Cherif M., Chicaud O., Olivrie A., Girault S.,Turlure P., J Abraham J., Bordessoule D.

Evaluation of a discharge instruction booklet for allograft patient.

40^ème Congrès European Bone Marrow transplantation, Milan, Italy 30 Mars– 2 Avril 2014

CH267

Deluche E., Monzat S.,Turlure P., Daly N., Devaud B.,Dauriac O., Bordessoule D., Girault S.

Prise en charge nutritionnelle des malades porteurs d’une leucémie aigüe myéloblastique au cours du traitement d’induction : réflexion sur les critères de dénutrition

Congrès 2014 de la Société Française d’Hématologie (SFH), Paris, 26-28 mars 2014

Hématologie, Mars 2014 (suppl 3)vol 20.

CH266

Zygar M., Philippon C., Otmane Cherif M., Gourin MP., Tardieu L., Girault S., Turlure P., Bordessoule D.

La sophrologie en soins de support pendant une allogreffe de CSH chez des patients atteints d’hémopathie maligne? Evaluation par les patients de ce soin complémentaire sur leur vécu.

Congrès 2014 de la Société Française d’Hématologie (SFH), Paris, 26-28 mars 2014

Communication orale

CH265

Zygar M., Moreau S., Philippon C., Trarieux-Signol S., Abraham J., Penot A., Dmytruk N., Gourin MP., Bordessoule D.

Intérêt de séances de sophrologie lors d’actes invasifs chez des patients atteints d’hémopathie maligne : expérience d’un service d’hématologie clinique.

Congrès 2014 de la Société Française d’Hématologie (SFH), Paris, 26-28 mars 2014

Hématologie, Mars 2014 (suppl 3)vol 20.

CH264

Signol N., Pham Dang A., Fargeas JB., Picat MA., Penot A., Vallejo C., Dantoine T., Bordessoule D.

Recours aux urgences des patients âgés atteints d’hémopathies malignes : impact de l’évaluation gériatrique sur le parcours de soinsCongrès 2014 de la Société Française d’Hématologie (SFH), Paris, 26-28 mars 2014
Hématologie, Mars 2014 (suppl 3)vol 20.

CH263

Touati M., Moreau S., Lefort S., Vergnenegre F., Brillat C., Lagarde A., Daulange A., Munyamahoro M., Lamarsalle L., Jaccard A., Vergnenegre A., Bordessoule D.

Le dispositif ESCADEHM de chimiothérapie injectable à domicile du réseau HEMATOLIM: évaluation médico-économique par modélisation d’une prise en charge alternée entre l’hôpital de jour et l’hospitalisation à domicile d’un traitement par bortézomib.

Congrès 2014 de la Société Française d’Hématologie (SFH), Paris, 26-28 mars 2014

Hématologie, Mars 2014 (suppl 3)vol 20.